{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-035913","form_type":"8-K","ticker":"LPCN","cik":"0001535955","company_name":"Lipocine Inc.","filed_at":"2026-08-04T10:08:32+00:00","discovered_at":"2026-08-04T10:10:02.144339+00:00","generated_at":"2026-08-04T10:10:11.917893+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Lipocine Q2 net loss $2.6M; Phase 3 PPD trial misses primary endpoint","bullets":["Net loss of $2.6M ($0.32 per share) vs $2.2M loss ($0.41 per share) in Q2 2025.","Cash and investments $23.3M at June 30, 2026, up from $14.9M at Dec 31, 2025.","Phase 3 trial of LPCN 1154 for PPD missed primary endpoint; post hoc analysis suggests efficacy; FDA meeting Q3 2026.","TLANDO royalty revenue $190k in Q2 2026, up from $123k; UAE approval for TESTYRA (TLANDO) received July 8, 2026.","New placebo-controlled trial for LPCN 1154 initiated to complement existing data."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-035913","json":"https://secwatch.observer/filing/0001493152-26-035913.json","markdown":"https://secwatch.observer/filing/0001493152-26-035913.md","text":"https://secwatch.observer/filing/0001493152-26-035913.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1535955/000149315226035913/0001493152-26-035913-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1535955/000149315226035913/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-04T10:10:11.917893+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}